26 stories from 10 sources

Public-health threats rise as healthcare business faces sharper scrutiny

Day’s Recap

Supporting Articles

12:41 AMBBC

Ebola outbreak in DR Congo becomes deadliest in its history

Summary

An Ebola outbreak in the Democratic Republic of Congo has become the deadliest in the country's history and the fastest-growing on record. It is being caused by Bundibugyo virus, a rare Ebola species.

The outbreak's speed and unprecedented death toll indicate that existing containment measures are failing to

Why it matters

A rapidly expanding outbreak involving a rare Ebola species raises the risk that standard response tools and local health capacity will prove insufficient.

3:39 PMCNBC

U.S. kindergarten vaccine coverage falls, CDC says

Summary

MMR vaccination coverage among U.S. kindergarteners has continued to decline since the COVID-19 pandemic, as measles cases rise. The falling coverage is eroding protection against a highly contagious disease.

The decisive shift is that routine childhood immunization has not recovered to pre-pandemic levels. Lower

Why it matters

Declining kindergarten vaccination rates are turning preventable measles outbreaks into a growing national risk.

10:40 AMStat News

STAT+: The IRS is probing UnitedHealth, and a private equity slowdown

Summary

UnitedHealth is facing an IRS investigation related to its tax payments. At the same time, private equity activity in physician-group deals is slowing.

The IRS inquiry adds regulatory and financial uncertainty to UnitedHealth's already complex business, while the

Why it matters

Tax scrutiny and weaker private equity demand point to a more constrained environment for healthcare consolidation and financial engineering.

4:30 AMStat News

STAT+: UnitedHealth faces IRS probe over potential tax avoidance

Summary

The IRS is examining whether UnitedHealth used arrangements that improperly reduced its tax liability. The dispute could leave the insurer facing a substantial increase in taxes.

The investigation creates a direct financial risk for UnitedHealth beyond its ongoing operating pressures. It

Why it matters

A major tax assessment would affect UnitedHealth's earnings and could raise compliance costs across the health insurance industry.

2:45 PMStat News

STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise

Summary

EyePoint said its experimental treatment for wet age-related macular degeneration did not maintain patients' vision when injections were given less frequently than with a standard treatment. The company nevertheless said the program may still have potential.

The failed comparison weakens the treatment's case as a longer-interval alternative to established therapy. EyePoint

Why it matters

The result undercuts a key value proposition for a treatment aimed at reducing the burden of repeated eye injections.

11:35 AMEconomic Times

EyePoint's drug for age-related eye disease fails late-stage trial, shares tank 70%

Summary

EyePoint's experimental drug Duravyu failed a late-stage trial for a serious age-related eye disease, sending the company's shares down about 70%. The company plans another trial and a potential FDA submission in 2027 as it seeks to challenge Regeneron's Eylea.

The failed trial sharply weakens EyePoint's near-term path to market and leaves investors dependent on

Why it matters

The result delays a potential competitor in a major eye-drug market and raises doubts about EyePoint's financing and development prospects.

9:57 AMBloomberg Markets

AstraZeneca Reports Mixed Lung Cancer Trial Results

Summary

AstraZeneca is stopping a late-stage trial of volrustomig after the experimental drug appeared unlikely to outperform existing lung cancer treatments. Separate trials produced positive results, including a Tagrisso and Orpathys combination for non-small cell lung cancer.

The decision removes one potential lung cancer asset, but the successful trials strengthen AstraZeneca's existing

Why it matters

AstraZeneca's lung cancer strategy remains viable, but its next growth phase will depend more heavily on proven franchises and combination therapies.

9:22 AMStat News

STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more

Summary

AstraZeneca is discontinuing a late-stage trial testing a drug in patients with metastatic non-small cell lung cancer. The decision adds to a recent run of setbacks for the company’s oncology pipeline.

The halted trial removes another late-stage opportunity in a highly competitive lung cancer market and

Why it matters

A late-stage failure can weaken a drugmaker’s growth outlook and reduce future treatment options for patients with advanced lung cancer.

12:01 AMStat News

STAT+: State laws may be curbing private equity takeovers of physician group

Summary

Private equity deals involving practice-management firms are declining sharply, as new state laws appear to be limiting investor takeovers of physician groups.

The shift suggests lawmakers are beginning to constrain private equity's role in medical practice ownership.

Why it matters

State ownership rules are starting to alter who can control physician practices and how healthcare consolidation proceeds.

12:00 PMMarketWatch

‘It’s a double-edged sword’: My husband got a $42,000 bonus. Will it wipe out our Affordable Care Act subsidy?

Summary

A household is weighing whether a $42,000 bonus could raise its income enough to reduce or eliminate its Affordable Care Act subsidy. The financial pressure has led to advice to return the bonus and borrow against home equity.

The bonus may create a tax and insurance-cost problem because ACA subsidy eligibility depends on

Why it matters

ACA subsidies can turn irregular income into a major insurance liability, making tax planning part of healthcare planning.

3:00 PMMarketWatch

My son does not work, yet pays $500 for Affordable Care Act health insurance. Is that fair?

Summary

The article examines a family's concern that an unemployed son pays $500 a month for Affordable Care Act coverage while some people with substantial assets but low taxable income qualify for subsidies. The dispute centers on how Marketplace assistance is calculated.

ACA subsidies are generally tied to reported household income, not wealth or employment status, which

Why it matters

The subsidy rules shape who can afford coverage and remain a persistent flashpoint in debates over ACA reform.

Other Developments

A curated list of other prominent stories from this day.

11:25 PMEconomic Times

Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness

Summary

Lupin received USFDA approval for generic pitolisant tablets, a treatment for excessive daytime sleepiness, strengthening its US generics portfolio. The stock remains below most key moving averages despite the approval, while foreign institutional investors increased their stake and mutual fund holdings fell.

The approval adds a new commercial opportunity but does not yet change the stock's weak

Why it matters

The approval could support Lupin's US growth, but execution and market competition will determine whether it translates into earnings and a sustained share-price recovery.

3:23 PMStat News

STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition

Summary

Sanofi plans to lay off 229 employees in Massachusetts, roughly a year after completing its $9.1 billion acquisition of Blueprint Medicines. The cuts affect one of the state's largest pharmaceutical employers.

The layoffs show Sanofi is reducing its local workforce even after using the acquisition to

Why it matters

The cuts raise questions about whether large pharmaceutical acquisitions create durable local growth or mainly consolidate operations.

2:42 PMCNBC

Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains

Summary

Eli Lilly and Johnson & Johnson shares rose after investors assessed new company data, while software stocks surrendered some of their gains from the previous week. The session reflected a rotation between healthcare names and higher-valued technology stocks.

The immediate shift was toward healthcare stocks with fresh data catalysts and away from software

Why it matters

The moves show how clinical and product data can redirect capital quickly across competing parts of the market.

1:23 PMNPR Arts

'Fed Up' author explains how evolution impacts eating, dieting and fat

Summary

Paleoanthropologist Daniel Lieberman discusses how evolutionary adaptations shape appetite, body fat and responses to modern diets, as well as the conflicting evidence behind nutrition advice.

The central point is that weight loss often collides with biological systems shaped to defend

Why it matters

An evolutionary lens challenges weight-loss narratives that place most responsibility on individuals.

12:24 PMPYMNTS

Patient Financing Becomes Part of the Healthcare Checkout

Summary

Healthcare providers are increasingly treating financing as part of the checkout process for costly services, including dental, vision and veterinary care. Payment timing can determine whether patients proceed with, reduce or delay treatment.

The shift moves financing from a back-office collection tool into the point-of-care purchasing decision. Providers

Why it matters

Embedding credit in healthcare checkout can expand access and revenue while making medical debt a more immediate consumer-finance risk.

9:38 AMStat News

STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

Summary

The lung cancer drug developed by Akeso and Summit is showing a worsening benefit on tumor progression. The broader biotech update also covers Europe's withdrawal of Tavneos over trial-integrity concerns and pricing questions around AstraZeneca's hypertension drug.

The deteriorating tumor-progression result weakens the drug's clinical and commercial outlook and could force investors

Why it matters

A weakening efficacy signal can undermine a major oncology program even as other regulatory and pricing pressures raise the sector's risk profile.

9:07 AMScienceDaily

Low-fat vegan diet helps people lose weight without eating less

Summary

In a 16-week clinical trial, participants following a low-fat vegan diet consumed about 357 fewer calories per day without counting calories, reducing portions or reporting persistent hunger. They ate nearly the same amount of food overall, with the change linked to the foods' lower calorie density.

The diet changed calorie intake through food composition rather than stricter restraint. That could make

Why it matters

The findings support dietary approaches that reduce energy intake without relying on hunger, tracking or portion control.

8:06 AMScienceDaily

Scientists uncover the hidden nerve network fueling breast cancer

Summary

Researchers found that triple-negative breast tumors may recruit macrophages to release BDNF, a protein that draws nerves into the tumor. These nerves may then support tumor growth, treatment resistance and spread.

The discovery identifies a potential cancer-supporting circuit linking immune cells, nerves and tumor tissue. If

Why it matters

A previously overlooked interaction between the immune and nervous systems may help explain why aggressive breast cancers resist treatment.

8:03 AMStat News

Everything the Trump administration did on health care last week

Summary

The administration issued an executive order reshaping the federal vaccine agenda, while Epic faced antitrust lawsuits and other health policy developments unfolded during the week. The review also covers the administration's broader health care actions.

The vaccine order signals a federal shift in how health policy priorities and oversight may

Why it matters

Federal vaccine policy and health-tech consolidation could change how patients, providers and drug companies operate.

4:30 AMStat News

Opinion: Paid paternity leave is pediatric preventive care

Summary

Pediatrician Nishant Pandya argues that paid paternity leave should be treated as a form of preventive care. He points to evidence that fathers make distinct contributions to children's health and development.

The case reframes paid leave as an intervention that can improve child health, not simply

Why it matters

Treating paid paternity leave as preventive care could broaden support for family policy within health systems and public programs.

4:30 AMStat News

STAT+: Epic confronts unprecedented challenges as it prepares to address customers and unveil road map

Summary

Epic is preparing for its annual User Group Meeting while facing an unusually difficult set of demands from the hospitals that rely on its software. The company is expected to use the meeting to address customers and present its future road map.

Epic's dominant position makes its next priorities consequential for hospitals, clinicians, and patients across the

Why it matters

Epic's product decisions can set the pace for health-record interoperability, clinical workflows, and technology spending across much of American medicine.

4:30 AMStat News

Opinion: We proved bipartisan health care reform works in North Carolina. Let’s bring it nationwide

Summary

Mandy Cohen and Kody Kinsley argue that North Carolina's health reforms show pragmatic, bipartisan policymaking can produce results. They call for applying that approach nationally.

The argument rests on treating North Carolina as evidence that cross-party cooperation can overcome health

Why it matters

The debate shifts from whether bipartisan reform is possible to whether its conditions can survive at national scale.

4:30 AMStat News

STAT+: Kennedy’s split-screen week: Talk of vaccines in D.C., fraud and addiction out West

Summary

Robert F. Kennedy Jr.’s California trip focused on fraud and addiction while vaccine issues dominated discussions in Washington. The contrasting agendas reflected his emphasis on selected Make America Healthy Again themes and his avoidance of more divisive subjects.

Kennedy is separating his public-health agenda by audience and venue rather than advancing one unified

Why it matters

Kennedy’s issue-by-issue strategy could expand his coalition while obscuring how his department would handle its most contentious responsibilities.

4:03 AMBloomberg Markets

Argenx Soars on Latest Trial Success for Autoimmune Drug Vyvgart

Summary

Argenx shares rose after the company reported another large successful trial for Vyvgart, its leading autoimmune drug.

The result adds to Vyvgart's clinical validation and strengthens the case for expanding its use

Why it matters

More positive data could extend Vyvgart's market opportunity and increase pressure on competing autoimmune treatments.

1:07 PMNYT New York

There’s a Way to Gauge Childhood Development. Why Isn’t It Used More?

Summary

A developmental screening tool is used in New York State less often than in almost any other state. Officials are launching a campaign to increase its use and identify developmental concerns earlier.

New York’s low screening rate creates a gap between children who may need support and

Why it matters

More consistent screening could connect children to developmental services before problems become harder and more expensive to address.

Make it yours

Build Your First Pass.

Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!